Home › Trials › NCT04776265

Evaluating Brentuximab Vedotin after Stem Cell Transplant in Hodgkin Lymphoma Patients

Real World Evidence of Brentuximab Vedotin Consolidation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Receive Salvage Chemotherapy and Autologous Stem Cell Transplant

Observational Grupo Argentino de Tratamiento de la Leucemia Aguda · NCT04776265

This study looks at how well Brentuximab Vedotin works as a follow-up treatment for adults with Hodgkin Lymphoma after they have a stem cell transplant.

Quick facts

Study typeObservational
Enrollment100 (estimated)
Ages18 Years and up
SexAll
SponsorGrupo Argentino de Tratamiento de la Leucemia Aguda Academic / other
Locations15 sites (Paraná, Entre Ríos and 14 other locations)
Trial IDNCT04776265 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather real-world evidence on patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who undergo autologous stem cell transplant (ASCT) in Argentina. It will assess the characteristics of these patients and the factors influencing the use of Brentuximab Vedotin (BV) as a consolidation therapy post-ASCT. Patients will be monitored according to local clinical practices, with data collected during routine follow-ups and treatment assessments. The study will include all eligible adult patients receiving ASCT, regardless of whether they receive BV consolidation.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 years or older with histologically confirmed relapsed or refractory classical Hodgkin Lymphoma undergoing ASCT.

Not a fit: Patients with relapsed or refractory Hodgkin Lymphoma who are not suitable for ASCT will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide insights into the effectiveness of Brentuximab Vedotin as a consolidation therapy, potentially improving outcomes for patients with relapsed or refractory Hodgkin Lymphoma.

How similar studies have performed: While this approach is observational, similar studies evaluating consolidation therapies in hematological malignancies have shown promising results, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients 18 years or older.
* All patients with histologically confirmed cHL who are primary refractory or relapse and receive ASCT as part of their salvage therapy.
* Signature of the form consent for participation in the study.

Exclusion Criteria:

* Patients with Relapsed/Refractory cHL not suitable for ASCT.

Where this trial is running

Paraná, Entre Ríos and 14 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hodgkin Lymphoma, AdultRelapsed Hodgkin's Disease, AdultRefractory Hodgkin LymphomaRelapsed/ Refractory Hodgkin LymphomaAutologous Stem Cell TransplantConsolidationBrentuximab Vedotin
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.